• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002932.SZ
Share

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Stocks

CN¥ 14.74Last Updated 16.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

CN¥ 490.71M

CN¥ 14.74
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. specializes in the research, development, manufacturing, and global distribution of in vitro diagnostic (IVD) reagents and related equipment. Their extensive product line features molecular diagnostics, including genetic tests for drug metabolism and pathogen nucleic acid detection kits, alongside immunodiagnostic and blood gas analysis solutions. Beyond diagnostics, the company delivers comprehensive information solutions for emergency and critical illness, which encompass specialized software, supporting hardware, and expert certification consulting. They also provide third-party medical testing services. These offerings are applied across a broad spectrum of medical fields, addressing conditions such as cardiovascular, kidney, infectious, diabetes, endocrine, and metabolic diseases, as well as obstetrics and gynecology. Furthermore, their products support prenatal and postnatal care, general health check-ups, and specific analyses for thyroid function, hormones, blood gases, coagulation, drug metabolism, and pathogen identification. Established in 2008, the company is headquartered in Wuhan, China.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is trading at neutral levels on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.07.2026 13:00

"Weeks, not months": The IEA warned of the threat of a global crisis over the Strait of Hormuz

16.07.2026 11:30

Strive has been paying dividends every day for a month now. What risks does the company face?

16.07.2026 10:45

Samsung and SK Hynix shares plummeted ahead of TSMC's earnings report. The market is waiting for signals regarding AI

16.07.2026 10:30

Morning Roundup: New Strikes on Iran, Anthropic Heads Toward an IPO, and a Sell-Off in Asia

16.07.2026 09:30

"Market Leaders Face a Test of Resilience": Goldman Explains How to Protect Your Portfolio

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026